Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21. September 2020 14:05 ET
|
Provectus Biopharmaceuticals Inc.
Complete response of all injected lesionsRegression of non-injected inguinal node, lung, and brain metastasesExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE...
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020
18. September 2020 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020 - A Phase 3 study concludes that a simplified regimen of...